| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
Centre for Oncology and Applied Pharmacology, University of Glasgow, Cancer Research UK Beatson Laboratories, Bearsden, Glasgow, United Kingdom
Requests for reprints: W. Nicol Keith, Centre for Oncology and Applied Pharmacology, University of Glasgow, Cancer Research UK Beatson Laboratories, Alexander Stone Building, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, United Kingdom. Phone: 44-141-330-4811; Fax: 44-141-330-4127; E-mail: n.keith{at}beatson.gla.ac.uk.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Chromatin immunoprecipitation assays. Cells were used when at 70% to 80% confluence and chromatin immunoprecipitation (ChIP) assays were done following the instructions recommended by the kit supplier (Upstate Biotechnology, Dundee, United Kingdom). Sonication was optimized to give chromatin fragments of around 500 bp to 1 kb in length (8 x 10-second pulses at 5 µm with 20-second rest between each pulse on ice using an MSE Soniprep150 sonifier). Resultant DNA from each immunoprecipitate was purified using the QIAquick PCR Purification Kit (Qiagen, West Sussex, United Kingdom). Also included in each experiment was a no antibody control immunoprecipitate to detect any background, which if present was subtracted from each immunoprecipitate within that experiment.
Antibodies. Antibodies used are the following: TriMeK4 H3, DiMeK9 H3, and TriMeK9 H3 (all Abcam, Cambridge, United Kingdom); DiMeK4 H3, DiMeK20 H4, TriMeK20 H4, AcH3, AcH4, and AcK9 H3 (all Upstate Biotechnology).
Quantitative PCR. Products from the ChIP assay were quantified by quantitative PCR on an Opticon2 DNA Engine (MJ Research, Inc., Waltham, MA) using primers to hTR and hTERT core promoter sequences and the SYBR Green Q-PCR Buffer (Finnzymes, Espoo, Finland). hTR primers, 29SF 5'-CCCGCCCGAGAGAGTGAC-3' and 5ALTR 5'-AAGTCAGCGAGAAAAACAGC and hTERT primers, TERTSF 5'-TCCCCT TCACGTCCGGCATT-3' and TERTSR 5'-AGCGGAGAGAGGTCGAATCG-3'.
Expression analysis. hTR expression was analyzed by quantitative PCR using the following primers: TRC3F, 5'-CTAACCCTAACTGAGAAGGGCGTA-3' and TRC3R, 5'-GGCGAACGGGCCAGCAGCTGACATT-3' and adjusted to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression (primers GAPDH0.45F 5'-ACCACAGTCCATGCCATCAC-3' and GAPDH0.45R 5'-CCACCACCCTGTTGCTGTA-3'). hTERT expression was analyzed by methods outlined in Keith et al. (8) using primers which detect all splice variants (primers HT2026F 5'-GCCTGAGCTGTACTTTGTCAA-3' and HT2482R 5'-GCCAAACAGCTTGTTCTCCATGTC-3'). hTERT expression is displayed as total amounts of all four main splice variants (wild type,
-deletion, ß-deletion, and
ß-deletion).
Trichostatin A and 5-azadeoxycytidine treatment. Cells were treated twice for 24 hours with 5-azadeoxycytidine (5-azadC, Sigma, Dorset, United Kingdom) to a final concentration of 2.5 µmol/L and treated for 16 hours with Trichostatin A (TSA, Upstate Biotechnology) at a final concentration of 350 nmol/L.
| Results |
|---|
|
|
|---|
|
Methylation of Lys9 histone H3 (MeK9 H3) facilitates the formation of heterochromatin (9, 10), and elevated levels of MeK9 H3 at promoter sequences are associated with repression of gene expression (11, 12). Figure 1B shows that MeK9 H3 is elevated in cells with low hTR expression (WI38, SUSM-1, KMST-6, and WI38-SV40) when compared with cells expressing relatively high levels of hTR (GM847, 5637, A2780, SKLU, and C33a), which were nearly devoid of MeK9 H3, showing that increased levels of MeK9 H3 at the hTR promoter are associated with repression of hTR gene expression.
Methylation of Lys20 histone H4 (MeK20 H4) is a mark of constitutive and facultative heterochromatin (13), but Fig. 1C shows that there is no clear link between MeK20 H4 and hTR expression. In this study, MeK20 H4 was only elevated in the ALT cell lines (GM847, SKLU, SUSM-1, KMST-6, and WI38-SV40), which may indicate a novel role for this modification.
Profile of transcriptionally permissive histone lysine modifications at the hTR promoter. Acetylated histones H3 and H4 (AcH3 and AcH4) are associated with euchromatin (14), and acetylation of promoter proximal histones is associated with gene expression (15, 16). Figure 1D shows that high levels of AcH3 and AcH4 are linked to elevated levels of hTR gene expression, with GM847, 5637, A2780, SKLU, C33a, and WI38 exhibiting higher levels of AcH3 and AcH4 than SUSM-1, KMST-6, and WI38-SV40. Higher levels of AcK9 H3 (Fig. 1E) are also observed in cell lines with higher expression.
Methylation of Lys4 histone H3 (MeK4 H3) is also associated with active gene transcription (17) and elevated levels have been observed at active gene promoters (18). Figure 1F indicates that high levels of MeK4 H3 are associated with elevated hTR gene expression with GM847, 5637, A2780, SKLU, C33a, and WI38 exhibiting higher levels of MeK4 H3 than SUSM-1, KMST-6, and WI38-SV40. This data shows that increased levels of MeK4 H3, AcH3 and H4, and AcK9 H3 at the hTR promoter sequence correlate with increased levels of hTR gene expression.
Overall, the data shows that distinct patterns of modifications present at the hTR promoter sequences are associated with gene expression (histone hyperacetylation, MeK4 H3, and lack of MeK9 H3) and gene repression (histone hypoacetylation, MeK9 H3, and lack of MeK4 H3). Interestingly, MeK20 H4 seems to mark for the ALT phenotype rather than being linked to gene repression.
Profile of repressive histone lysine methylation at the hTERT promoter. As for hTR, we first established hTERT gene expression levels from each cell line. As Fig. 2A shows, of the cell lines studied, only the tumor cell lines (C33a, A2780, and 5637) have appreciable levels of hTERT gene expression. Apart from the GM847 cell line, which expresses very low amounts of hTERT, the ALT and normal cell lines showed no hTERT expression. The profile of the chromatin environment surrounding the hTERT promoter was then investigated.
|
As with the hTR promoter, MeK20 H4 is observed at higher levels at the hTERT promoter in the ALT cell lines in which only GM847 has any hTERT expression. In contrast normal fibroblasts (WI38) have levels of MeK20 H4 that are comparable with those found in hTERT-expressing tumor lines suggesting that either different mechanisms of repression exist in ALT and normal cells or that MeK20 H4 has a role other than in gene repression (Fig. 2C).
Profile of transcriptionally permissive histone lysine modifications at the hTERT promoter. Acetylation of promoter histones H3 and H4 are generally considered to allow the gene to be permissive for transcription. Figure 2D and E show that the two tumor cell lines expressing the highest levels of hTERT (C33a and A2780) have the highest levels of AcH3, AcH4, and AcK9 H3. However, 5637, which express a relatively high level of hTERT, has acetylation levels comparable with that of the nonexpressing cell lines. The ALT and normal cell lines that do not express hTERT (except for very low amounts in GM847) show low acetylation of AcH3, AcH4, and AcK9 H3.
Although MeK4 H3 is associated with active gene expression all the cell lines exhibited some degree of MeK4 H3 whether they express hTERT or not. However, apart from the KMST-6 cell line, MeK4 H3 is higher in the hTERT-expressing tumor cell lines (C33a, A2780, and 5637) than in the hTERT-nonexpressing normal and ALT cell lines Fig. 2F.
Thus, as with hTR, the data shows that distinct patterns of modifications present at the hTERT promoter sequences are associated with gene expression (histone hyperacetylation, MeK4 H3, and lack of MeK9 H3) and gene repression (histone hypoacetylation and MeK9 H3). Interestingly, MeK20 H4 again seems to mark for the ALT phenotype rather than being linked to gene repression.
Reactivation of telomerase gene expression by chromatin remodeling. As active hTR and hTERT promoters show similar patterns of histone modifications (high levels of AcH3, AcH4, AcK9 H3, and MeK4 H3), we asked whether expression of repressed telomerase genes in telomerase-negative cells could be induced by promoting such modifications. TSA, a histone deacetylase inhibitor and 5-aza-dC, a DNA methylation inhibitor were used in combination to induce chromatin remodeling.
Treatment of KMST-6, WI38, and WI38-SV40 with TSA and 5-azadC in combination resulted in increases in hTR gene expression (Fig. 3A) associated with increases in acetylation (Fig. 3B and C), apart from AcH3 level in KMST-6 which does not change upon treatment. Increases in MeK4 H3 were also associated with increases in expression in KMST-6 and WI38, although they decreased in WI38-SV40 (Fig. 3D).
|
|
| Discussion |
|---|
|
|
|---|
This study also suggests that modulation of the chromatin environment of the telomerase gene promoters could influence which telomere maintenance mechanism is used. Telomerase reactivation may occur by chromatin remodeling allowing a more permissive state of transcription to occur at the hTR and hTERT promoters. Conversely, the ALT phenotype may arise due to the tight repression of the hTR and/or hTERT promoter, caused by chromatin remodeling of the promoter sequences. Chromatin remodeling events that cause increased levels of repressive modifications to concentrate at promoter sequences may "force" a cell to use the ALT telomere maintenance mechanism rather than that of telomerase activity, due to the inability of the cell to reexpress either hTR or hTERT. Alternatively, the promoter may accumulate heterochromatic changes because there is no need for telomerase in these cells once ALT is activated.
Further studies identifying the proteins involved in modulating the chromatin environment of the hTR and hTERT promoters may allow identification of new regulatory pathways, provide therapeutic drug targets, and allow further understanding of the processes controlling telomerase gene expression in normal development and tumorigenesis. Specific targeting by chromatin remodeling enzymes to the hTR and hTERT promoters to allow a level of transcriptional control is also an exciting prospect.
Overall our results suggest that the modulation of the chromatin environment has an important role in regulating telomerase gene expression and may be a significant factor in the acquirement of the ALT phenotype by some tumor cells.
| Acknowledgments |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| Footnotes |
|---|
Received 5/18/05. Revised 6/13/05. Accepted 6/22/05.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
X. Zhang, I. Neganova, S. Przyborski, C. Yang, M. Cooke, S. P. Atkinson, G. Anyfantis, S. Fenyk, W. N. Keith, S. F. Hoare, et al. A role for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6 and CDC25A J. Cell Biol., January 12, 2009; 184(1): 67 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Chen, H. G. Campbell, A. K. Wiles, M. R. Eccles, R. R. Reddel, A. W. Braithwaite, and J. A. Royds PAX8 Regulates Telomerase Reverse Transcriptase and Telomerase RNA Component in Glioma Cancer Res., July 15, 2008; 68(14): 5724 - 5732. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Atkinson, C. M. Koch, G. K. Clelland, S. Willcox, J. C. Fowler, R. Stewart, M. Lako, I. Dunham, and L. Armstrong Epigenetic Marking Prepares the Human HOXA Cluster for Activation During Differentiation of Pluripotent Cells Stem Cells, May 1, 2008; 26(5): 1174 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hadnagy, R. Beaulieu, and D. Balicki Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics Mol. Cancer Ther., April 1, 2008; 7(4): 740 - 748. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Saretzki, T. Walter, S. Atkinson, J. F. Passos, B. Bareth, W. N. Keith, R. Stewart, S. Hoare, M. Stojkovic, L. Armstrong, et al. Downregulation of Multiple Stress Defense Mechanisms During Differentiation of Human Embryonic Stem Cells Stem Cells, February 1, 2008; 26(2): 455 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Liu, X. Fang, Z. Ge, M. Jalink, S. Kyo, M. Bjorkholm, A. Gruber, J. Sjoberg, and D. Xu The Telomerase Reverse Transcriptase (hTERT) Gene Is a Direct Target of the Histone Methyltransferase SMYD3 Cancer Res., March 15, 2007; 67(6): 2626 - 2631. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Costa, M. G. Daidone, L. Daprai, R. Villa, S. Cantu, S. Pilotti, L. Mariani, A. Gronchi, J. D. Henson, R. R. Reddel, et al. Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. Cancer Res., September 1, 2006; 66(17): 8918 - 8924. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |